Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Bayer AG is conducting a Phase 1 clinical study titled ‘A Phase 1 Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of 225Ac-PSMA-Trillium in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)’. The study aims to assess the safety and efficacy of 225Ac-PSMA-Trillium, a novel treatment for mCRPC, a prostate cancer that has spread and is resistant to hormone therapy. The study’s significance lies in its potential to offer a new therapeutic option for patients with limited treatment choices.
The intervention being tested is 225Ac-PSMA-Trillium (BAY3563254), a drug designed to bind to PSMA and emit radiation to destroy cancer cells. This treatment is administered via intravenous injection every six weeks.
The study employs a non-randomized, sequential intervention model with no masking, focusing primarily on treatment. It consists of two parts: dose escalation to determine the optimal dose, followed by dose expansion to assess efficacy at the identified dose.
The study commenced on March 7, 2024, with an estimated completion date yet to be determined. The latest update was submitted on July 14, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This clinical trial could significantly impact Bayer’s stock performance by potentially introducing a breakthrough treatment in the prostate cancer market. Positive outcomes may enhance investor confidence and position Bayer competitively against other pharmaceutical companies in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.